OPT-302 Phase 2b in wet AMD

A multicenter, randomized, double-masked, sham controlled study of intravitreal OPT-302 in combination with ranibizumab, in participants with wet AMD

Data presented by Professor Timothy Jackson PhD., FRCOphth., King's College London
EURETINA Congress, Thursday 5th September 2019

Contact: Megan Baldwin PhD, CEO and Managing Director, Opthea Limited

Disclaimer

Investment in Opthea Limited ('Opthea') is subject to investment risk, including possible loss of income and capital invested. Neither Opthea nor any other member company of the Opthea Group guarantees any particular rate of return or performance, nor do they guarantee the repayment of capital.

This presentation is not an offer or invitation for subscription or purchase of or a recommendation of securities. It does not take into account the investment objectives, financial situation and particular needs of the investor. Before making any investment in Opthea, the investor or prospective investor should consider whether such an investment is appropriate to their particular investment needs, objectives and financial circumstances and consult an investment advisor if necessary.

This presentation may contain forward-looking statements regarding the potential of the Company's projects and interests and the development and therapeutic potential of the company's research and development. Any statement describing a goal, expectation, intention or belief of the company is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercialising drugs that are safe and effective for use as human therapeutics and the financing of such activities. There is no guarantee that the Company's research and development projects and interests (where applicable) will receive regulatory approvals or prove to be commercially successful in the future. Actual results of further research could differ from those projected or detailed in this presentation. As a result, you are cautioned not to rely on forward-looking statements. Consideration should be given to these and other risks concerning research and development programs referred to in this presentation.

OPTHEA

OPT-302 Inhibits VEGF-C and VEGF-D





- Potent inhibitor of VEGF-C (~5pM) and VEGF-D (~0.5 nM)
- A 'trap' that blocks VEGF-C and VEGF-D binding to the receptors VEGFR-2 and VEGFR-3

 # Bevacizumab is used 'off-label' for the treatment of nAMD

VEGF-A Inhibition Upregulates VEGF-C/D

Upregulation in Neovascular AMD [1]



[1] *Cabral et al., Bevacizumab injection in patients with neovascular Age-Related Macular Degeneration increases angiogenic biomarkers, Opthalmol Retina, 2(1): 31-37, 2018*

OPTHEA

OPT-302-1002 – Study Overview

ClinicalTrials.gov Identifier: NCT03345082

Randomised 1:1:1 to treatment arms : intravitreal dosing every 4 weeks (x 6)



OPTHEA

Study Overview



CNV – choroidal neovascularisation; LTFU – lost to follow up

Study Outcome Measures

Primary Outcome:

- Mean change from Baseline in ETDRS best corrected visual acuity at Week 24

Key Secondary Outcomes at Week 24:

- Patients gaining ≥15 or more ETDRS letters
- Patients losing ≥15 or more ETDRS letters
- Change in central subfield thickness (SD-OCT)
- Change in subretinal fluid and intraretinal fluid (SD-OCT)

Key Exploratory Outcomes at Week 24:

- Change in total lesion area and choroidal neovascularisation (CNV) area

Key Safety Outcome:

- Safety and tolerability

OPTHEA

Study Demographics and Baseline Characteristics

Evenly balanced across groups

Demographic / Baseline Disease Characteristic	Sham + ranibizumab N=121	0.5 mg OPT-302 + ranibizumab N=122	2.0 mg OPT-302 + ranibizumab N=123
Mean Age – years ± SD	76.1 ± 9.48	78.8 ± 8.16	77.8 ± 8.82
Sex – n (%)			
Male	48 (39.7%)	49 (40.2%)	45 (36.6%)
Female	73 (60.3%)	73 (59.8%)	78 (63.4%)
Caucasian Race – n (%)	117 (99.2%)	119 (99.2%)	117 (97.5%)
Mean Visual Acuity (BCVA) – letters ± SD	50.7 ± 10.21	51.1 ± 8.96	49.5 ± 10.26
Mean Total Lesion Area - mm^2 ± SD	6.08 ± 3.21	6.48 ± 3.30	6.62 ± 3.39
Lesion type			
Predominantly classic – n (%)	15 (12.4%)	15 (12.3%)	16 (13.0%)
Minimally classic – n (%)	53 (43.8%)	51 (41.8%)	53 (43.1%)
Occult - n (%)	53 (43.8%)	56 (45.9%)	54 (43.9%)
Mean central subfield thickness (CST) - mm ±SD	412.10 ± 110.62	425.18 ± 120.45	414.12 ± 123.25
Sub-retinal fluid (SRF) present – % participants	89.3%	84.4%	87.8%
Intra-retinal cysts present – % participants	57.9%	63.9%	56.1%

Intent-to-Treat (ITT) population; SD: standard deviation; BCVA: Best Corrected Visual Acuity

OPTHEA

Primary Analysis – Mean Change in BCVA Baseline to Week 24

Primary endpoint achieved

OPT-302 Combination Therapy Demonstrated Superiority in Visual Acuity over Ranibizumab



Modified Intent-to-Treat (mITT) population; BCVA – Best Corrected Visual Acuity;
Graph represents difference in Least Square Means, using Model for Repeated Measures (MRM) analysis, and standard error of the mean (SEM);
Control of Type I error via the Hochberg Procedure

OPTHEA

Mean Change in BCVA Over Time

Additive benefit of OPT-302 evident from 8-weeks



mITT; graph represents "as observed" data and SEM

Mean Change in Central Subfield Thickness - Baseline to Week 24

Reductions in CST in OPT-302 combination groups compared to sham + ranibizumab



mITT; as observed; CST – central subfield thickness

Sub-retinal Fluid and Intra-retinal Cysts at Week 24

Fewer participants with retinal fluid present in OPT-302 combination groups compared to sham + ranibizumab



mITT; as observed; SRF – sub-retinal fluid; IR – intra-retinal

OPTHEA

Mean Change in Total Lesion Area and CNV Area – Baseline to Week 24

Greater reduction in Total Lesion and CNV Area in OPT-302 combination groups compared to sham + ranibizumab



mITT; as observed; CNV – choroidal neovascularisation; Difference in Least Square Means

OPTHEA

Safety – Adverse Events (AEs)

N Participants (%)	Sham + ranibizumab N=121	0.5 mg OPT-302 + ranibizumab N=120	2.0 mg OPT-302 + ranibizumab N=124
Treatment emergent AEs	84 (69.4%)	87 (72.5%)	93 (75.0%)
Ocular AEs - Study Eye – related to study product(s)[1]	17 (14.0%)	17 (14.2%)	19 (15.3%)
Ocular AEs - Study Eye – Severe[2]	1 (0.8%)	2 (1.7%)	1 (0.8%)
Serious AEs	10 (8.3%)	16 (13.3%)	7 (5.6%)
Ocular SAEs in Study Eye	0 (0.0%)	2[3] (1.7%)	0 (0.0%)
Intraocular inflammation[4] – Study Eye	0 (0.0%)	2[3] (1.7%)	1[5] (0.8%)
AEs leading to study IP discontinuation only	2 (1.7%)	3 (2.5%)	0 (0.0%)
AEs leading to study discontinuation	1[6] (0.8%)	0 (0.0%)	0 (0.0%)
Any APTC event	0 (0.0%)	1[7] (0.8%)	0 (0.0%)
Deaths	2[8] (1.7%)	0 (0.0%)	0 (0.0%)

Safety population analysed according to medication received

[1] Assessed by investigator to be "possibly related", "probably related" or "definitely related" to administration of study drug(s)

[2] Assessed by Investigator to be National Institutes of Health (NIH) Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or above, or, if CTCAE grade is unavailable, an AE assessed as "causing an inability to perform normal daily activities"

[3] SAE of endophthalmitis, with AEs of hypopyon and anterior chamber cell (n=1), SAE of vitritis (n=1)

[4] AEs considered to be indicative of intraocular inflammation, defined prior to database lock as: Endophthalmitis, iritis, vitritis, iridocyclitis, uveitis, hypopyon, viral iritis, or anterior chamber inflammation

[5] Anterior chamber cell (trace 1-4 cells)

[6] Squamous cell carcinoma of the lung diagnosed shortly after Baseline visit

[7] Non-fatal myocardial infarction

[8] Pneumonia (n=1), infective endocarditis (n=1)

OPTHEA

Thank you to all study participants and over 100 sites across 10 countries



Czech Republic – 3 sites
France – 6 sites
Hungary – 5 sites
Italy – 5 sites
Israel – 8 sites
Latvia – 4 sites
Poland – 7 sites
Spain – 8 sites
United Kingdom – 7sites
United States – 56 sites

HEA

Conclusions

- **Phase 2b trial met primary endpoint**
  - OPT-302 (2.0 mg) combination therapy demonstrated superiority in visual acuity over ranibizumab + sham
  - Vision gain of 3.4 letters
  - Statistically significant (p=0.0107)
  - High ranibizumab control arm

- **Secondary outcomes were supportive of the primary endpoint:**
  - **Vision**
    - More patients gained ≥ 15 letters of vision
    - Fewer patients lost ≥ 15 letters of vision
  - **Retinal anatomical improvements**
    - Reductions in CST, subretinal and intraretinal fluid
    - Greater decreases in Total Lesion Area and CNV Area

- **Favourable safety profile similar to ranibizumab alone**

OPTHEA

Megan Baldwin
CEO & Managing Director

T +61 (3) 9826 0399
E megan.baldwin@opthea.com

Suite 0403, Level 4,
650 Chapel Street,
South Yarra 3141 Victoria Australia
www.opthea.com